Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triiodothyronine to accelerate antidepressant effects of escitalopram
2007-001540-45Phase 3Completed
- Sponsor
- Institute of Psychophysiology and Rehabilitation
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive episode (MDE) and major depressive disorder (MDD) comparing Escitalopram + Triiodothyronine with Escitalopram + Placebo (2 arms). Primary endpoints: Early change in Ham-D total score and Safety of escitalopram + triiodothyronine. Started Mar 2007; status: completed.
02
Drugs
liothyronine
03
Conditions
major depressive episode (MDE)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-001540-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001540-45.